BA.5 ups concerns about spread, hospitalizations
The Food and Drug Administration authorized Novavax’s COVID-19 shot for emergency use on Wednesday, adding a fourth vaccine to the U.S. arsenal.
The agency cleared the vaccine for adults aged 18 and older. The shot will be administered as a two-dose primary series, three weeks apart.
Novavax’s shot “provides another alternative for adults and adds another vaccine to the COVID-19 vaccine supply for the United States. The American public can trust that this vaccine, like all vaccines that are used in the United States, has undergone the FDA’s rigorous and comprehensive scientific and regulatory review,” said Peter Marks, director of the FDA’s vaccine division.
Once the Centers for Disease Control and Prevention signs off, vaccination can begin. The agency’s Advisory Committee on Immunization Practices is scheduled to meet on July 19.
WORLD COVID STATS
Highlighted in green
= all cases have recovered from the infection